BioXcel Therapeutics (NASDAQ:BTAI) released its earnings results on Tuesday. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.02), Bloomberg Earnings reports.
BTAI stock traded down $0.84 during trading on Wednesday, reaching $8.01. 2,427 shares of the stock traded hands, compared to its average volume of 22,448. The firm’s 50 day simple moving average is $10.76. BioXcel Therapeutics has a 52-week low of $2.41 and a 52-week high of $12.00. The company has a quick ratio of 5.59, a current ratio of 5.59 and a debt-to-equity ratio of 0.04. The firm has a market cap of $138.68 million, a price-to-earnings ratio of -5.88 and a beta of 3.02.
BTAI has been the subject of several analyst reports. Zacks Investment Research lowered BioXcel Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. HC Wainwright set a $25.00 price target on BioXcel Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 5th. Finally, ValuEngine downgraded BioXcel Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 8th.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Read More: Call Option
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.